Cerebrolysin
← Back to LibraryCompound Profile
Cerebrolysin is reviewed here for cognition, mood, and brain-health context.
Research Summary
Human studies, published literature, supporting research
Cognition, Mood, Brain health
Target context: BDNF; NGF; GDNF; CNTF
Human data exists, but longer-term context is still developing.
Human research exists, but confidence depends on product, dose, and population.
Route(s)
Subcutaneous, Intramuscular
Typical dose
5mg
Dosing window
Morning
Receptor / target
BDNF; NGF; GDNF; CNTF
Properties
Not listed
Pre-mixed
No
How Cerebrolysin is studied in the brain
Cerebrolysin research is mostly discussed around stroke, brain injury, motor recovery, and cognition.
Injury Area — Brain Recovery
Human and preclinical researchStudied for recovery following stroke or brain injury.
Motor Cortex — Movement
Stroke-recovery researchStudied for motor recovery and improved physical function after stroke.
Memory Area — Cognition
Mixed human evidenceStudied for memory and cognitive recovery, but findings are mixed.
Protocols
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-30 | 5mg 1x daily | Administer 5 days per week for 30 days. |
Protocol example for research-context comparison; verify against the evidence status and listed medical sources.
Alternative Titration
| Timeframe | Dose | Notes |
|---|---|---|
| Week 1 | 20 mg 1x daily | Loading phase. |
| Week 2 | 24 mg daily | Split: 12mg AM + 12mg PM. |
| Week 3 | 28 mg daily | Split: 14mg AM + 14mg PM. |
| Weeks 4-6 | 32 mg daily | Split: 16mg AM + 16mg PM. |
Alternative research-context example; not an approved-label regimen unless marked above.
Protocol logic check
Medical literature and study context
Medical-source summary: This section ties the page to medical literature, drug labels, trial registries, and regulatory sources. It is educational context only and should not be read as medical advice or a use recommendation.
| Evidence position | No approved FDA label was identified for this entry; evidence should be treated as literature context rather than validated dosing guidance. |
|---|---|
| Where studied | Studied in neuroprotection, cognition, anxiety, sleep, stroke, neuropathy, or neuropeptide models depending on the target and route. |
| Source systems checked | FDA regulatory pages; PubMed/PMC literature; ClinicalTrials.gov records |
| Target and route context | Target/receptor: BDNF; NGF; GDNF; CNTF. Route(s): Subcutaneous, Intramuscular. Dosing window on page: Morning. |
| Protocol anchor | No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only. |
| Main evidence limit | Key limitation: literature may be preclinical, indirect, old, region-specific, or sparse; absence of a label means no validated dosing standard. |
Source-linked findings
- Nootropic and neuropeptide claims need separation between animal neuroprotection, regional clinical literature, and modern randomized human trials.
- Sleep, anxiety, psychiatric history, blood pressure, and route-specific delivery are common practical limits.
- No approved-label regimen was identified for this entry. Dosing examples should be treated as unverified protocol examples.
Protocol and study notes
- No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only.
- On-page protocol examples summarized for comparison: Standard Protocol: Days 1-30, 5mg 1x daily; Alternative Titration: Week 1, 20 mg 1x daily.
- Key limitation: literature may be preclinical, indirect, old, region-specific, or sparse; absence of a label means no validated dosing standard.
- Monitor sleep, anxiety or mood activation, blood pressure, seizure history, psychiatric history, and route-specific nasal or injection irritation.
Selected medical sources
Independent evidence
Regulatory status: no approved label identified
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Severe renal impairment: the free amino acid component of Cerebrolysin (75% of the preparation) places a nitrogen load on renal clearance pathways; in subjects with severely reduced GFR, amino acid accumulation and metabolic byproduct buildup is a meaningful concern.
- Epilepsy or active seizure disorders: Cerebrolysin has been associated with lowering the seizure threshold in susceptible individuals through its neurostimulatory and glutamatergic modulatory activity; contraindicated in subjects with uncontrolled seizure disorders.
- Active status epilepticus: absolute contraindication.
- Known hypersensitivity to porcine-derived biological products: Cerebrolysin is derived from porcine brain; subjects with pork allergies or hypersensitivity to porcine proteins carry a risk of allergic reaction ranging from injection site reaction to systemic anaphylaxis.
- Active malignancy involving the CNS: neurotrophic growth factor activity (NGF, BDNF, GDNF) from Cerebrolysin could theoretically support tumor cell survival and proliferation in brain tumors expressing Trk receptors.
- Pregnancy: no clinical safety data; neurotrophic factor delivery during CNS development has not been established as safe.
- Breastfeeding: no safety data.
- Concurrent use with MAO inhibitors: potential pharmacodynamic interaction through serotonergic and noradrenergic modulation.
- Acute stroke during the hyperacute phase (first 4-6 hours): Cerebrolysin clinical protocols specify administration after the hyperacute window; early intervention timing is a clinical judgment requiring medical supervision.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Injection site soreness: the primary and most consistent adverse effect with IM administration; larger volume injections into muscle produce mechanical distension and mild inflammatory response; more pronounced with higher doses (20-32mg/day split IM); typically resolves within 24-48 hours.
- Mild flu-like symptoms: low-grade fever, malaise, mild chills; reported in a subset of users during the first 1-2 weeks of a new cycle; likely related to the immune response to the porcine-derived biological extract; typically self-limiting.
- Dizziness and lightheadedness: uncommon; reported in subjects receiving higher doses; mechanism not fully characterized; mild and transient.
- Nausea: mild; reported in a small subset; more common with faster injection rates; slow administration mitigates.
- Headache: uncommon; reported in the initial days; may reflect the rapid changes in neurotrophic factor signaling in cerebrovascular and neural tissue.
- Agitation or restlessness: paradoxical stimulant-like response in a small subset of users; the NGF-mediated cholinergic activation in some subjects produces heightened arousal rather than cognitive clarity; usually resolves within the first week.
- Allergic reactions: ranging from local injection site erythema and urticaria to (rarely) systemic allergic responses in porcine-sensitive subjects; the porcine biological origin is the source of this risk.
- Potential seizure threshold lowering: the primary serious adverse effect documented in clinical trial safety data; most relevant in subjects with pre-existing epileptiform activity; routine use in healthy subjects at standard doses is not associated with seizure induction.
- Insomnia: reported by a minority of subjects with morning IM or subcutaneous dosing, particularly at higher doses; related to neurostimulatory NGF/BDNF activation of arousal circuits; manage with strict morning administration.
Compatibility
The relationships below are heuristic compatibility notes and were not independently verified. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.